Search Results
Results found for "Fubiao Shi"
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
The team only finds out when timelines shift. resolved when you rebuild how decisions are made and what truly matters inside your company. 1️⃣ The first shift deliverables but empty of decision triggers, you’re burning runway without building value. 2️⃣ The second shift When these lines blur, so do accountability and execution. 3️⃣ The third and hardest shift is restoring But the moment they shift from disconnected workstreams to a shared, milestone-driven roadmap tied to
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
And that shift changed everything. in both the periphery and brain Being able to see receptor distribution is not just aesthetic — it shifts
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
signaling pathways Experimentally accessible Deeply relevant to metabolic disease and obesity This shift
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
It infers the affinity (Kᵦ) of an antagonist by linking concentration shifts to receptor occupancy. Criteria for genuine competition: Parallel rightward shift of the agonist concentration–response curve When these same molecules act as antagonists, their curves shift not only in position but also in shape Defined as the negative log of the antagonist concentration that causes a twofold agonist EC₅₀ shift
- How Schild Analysis Protects Your Conclusions in GPCR Research
This Week in Premium: Sneak Peek Industry insights: Domain CMO; Pfizer–Metsera; Novo Nordisk strategy shifts Terry’s Corner: Schild Analysis — Why It Matters Most assays show a clean rightward shift and we assume Use the four canonical criteria to distinguish genuine orthosteric antagonism from apparent shifts that
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
✅ This post explores how scientific thinking can become a leadership liability and what mindset shifts Trying to eliminate all risk leads to overengineering and stagnation . 👉 Instead of shipping early and It requires conscious shifts in how you process uncertainty, how you frame decisions, and how you lead ✅ The shift from scientist to CEO is not about abandoning your expertise.
- How GPCR Collaboration Built an Innovation Engine
The lab went from project-level thinking to platform-level strategy — a critical shift for GPCR biology
- From Pipettes to Platforms: The Evolution of GPCR Research
Michelle notes that the real shift wasn’t just speed. It was confidence. The Mindset Shift: From Technique to Strategy Michelle reflects on how early-career researchers once As technology absorbs the “how,” human expertise shifts to the “why” and “what if.” Timeline: Manual assay years — technical rigor as foundation Technology boom — scaling curiosity Strategic shift
- How GPCR Spatial Signaling Sparked a Scientific Journey
But something shifted. A single experiment worked. Then another didn’t. This shift—from passive observer to active investigator—wasn’t about external validation.
- Molecular creativity in drug discovery
. 🔍 This Week in Premium: Sneak Peek Industry insights: New alliances, pipeline shifts, and platform Michelle Halls dissects how spatial GPCR signaling shifts discovery—and how leadership, mentorship, and
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
This is a philosophical shift: Instead of asking, “Which proteins are related?” They are allosteric machines , able to shift conformational states in response to multiple binding influences
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
That shift—from describing the past to forecasting the future—is what makes predictive GPCR modeling
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
of bad ideas—they’re paused when the chemical matter isn’t compelling enough or when strategic focus shifts
- Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!
Logo Contest : Let your creativity shine by submitting your design for the Logo Contest before August in Medicinal Chemistry NEW October 17, 2024 | Unprecedented fragment-based screening using Spectral Shift
- From Failed Experiments to Predictive GPCR Models
That recognition shifted everything. Predictive GPCR-Ligand Modeling Carlsson's work quickly shifted from curiosity to impact. For Carlsson, this marked a shift in how his lab approached GPCR research. While these tools aren’t perfect—and sometimes fail in unexpected ways—they represent a shift in what
- Irreversible Drugs, Real Control: Design for Durable Target Engagement
Trial ➤ DrGPCR Podcast: Jens Carlsson on Predictive Modeling Prediction over explanation—that’s the shift
- Innovative Data-Driven Solutions: The pHSense Revolution
These probes shift brightness and fluorescence lifetime as pH changes. “Don’t chase the shiny imaging tool if it doesn’t scale.
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
GPCRs in Medicinal Chemistry October 17, 2024 | Unprecedented fragment-based screening using Spectral Shift
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
The metrics shift: k_inact (rate of inactivation) replaces static Ki values. k_inact/KI becomes the
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
Why This Matters: IP-One helped set a new gold standard for functional GPCR assays—shifting how compounds Dual control: not just brightness but fluorescence lifetime, with drastic shifts as pH drops.
- Understanding Enzyme Inhibition In GPCR Discovery Programs
This week —NIH’s new GPCR biosensor push, a leadership shift at Septerna, and a bold thesis on stabilizing You’ll explore how catalytic control, allosteric shifts, and CYP450 behavior rewrite the rules of pharmacology
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
That same shift in mindset (seeing enzymes as predictable, targetable, quantifiable systems ) is exactly Their broad substrate tolerance shields us from xenobiotics.
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
Inside Premium: Key FDA moves reshaping GPCR pipelines, shifting obesity and CNS strategies, and global to explore how computational modeling is evolving from explanation to real prediction — and why that shift
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
By modulating receptor expression or sensitivity, we can shift the “lens” through which drug activity
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
. ✅ Insight into Consequences: How binding sites determine receptor state shifts, signaling outcomes Allosteric sites operate differently: ligands bind elsewhere, transmit energy changes, and shift the This has immediate implications for interpreting EC50 shifts, partial agonism, and assay readouts—especially orthosterically, allosterically, or with mixed mechanisms—and why that matters for interpreting EC₅₀ shifts
- Why Opposing Processes Matter for Your Next GPCR Drug
Some can make a mediocre drug shine. Get a sense of why inverse agonists may be necessary to truly shift the physiological balance.
- The Five Traps of Ignoring Kinetics
Instead of clean monophasic curves, you’ll see biphasic signatures or sequential shifts—first cholinesterase It’s a shift in how expert drug hunters see pharmacology.
- From Snapshots to Predictions: Why Mechanism of Action Matters
A compound shifts the curve. It elevates the baseline. But what does that really mean? Take the example Terry highlights: an agonist curve with a rightward shift and elevated baseline. The shift continues linearly. Allosteric? The shift plateaus once the allosteric site saturates. compound produced four completely different assay signatures depending on the system: Sometimes it shifted It’s a shift in how you approach discovery.
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
Superluminal is building systems that learn from receptor movement, conformational shifts, and complex emphasizes that building a startup is not simply a continuation of research — it requires a mindset shift
- Understanding the Journey: Catherine Demery's Path to Addiction Science
But something shifted.






























